Regulation of endocytosis via the oxygen-sensing pathway

Tumor hypoxia is associated with disease progression, resistance to conventional cancer therapies and poor prognosis. Hypoxia, by largely unknown mechanisms, leads to deregulated accumulation of and signaling via receptor tyrosine kinases (RTKs) that are critical for driving oncogenesis. Here, we show that hypoxia or loss of von Hippel–Lindau protein—the principal negative regulator of hypoxia-inducible factor (HIF)—prolongs the activation of epidermal growth factor receptor that is attributable to lengthened receptor half-life and retention in the endocytic pathway. The deceleration in endocytosis is due to the attenuation of Rab5-mediated early endosome fusion via HIF-dependent downregulation of a critical Rab5 effector, rabaptin-5, at the level of transcription. Primary kidney and breast tumors with strong hypoxic signatures show significantly lower expression of rabaptin-5 RNA and protein. These findings reveal a general role of the oxygen-sensing pathway in endocytosis and support a model in which tumor hypoxia or oncogenic activation of HIF prolongs RTK-mediated signaling by delaying endocytosis-mediated deactivation of receptors.

[1]  B. Deurs,et al.  A Key to Lysosome Biogenesis , 2000 .

[2]  T. Meyer,et al.  PI(3,4,5)P3 and PI(4,5)P2 Lipids Target Proteins with Polybasic Clusters to the Plasma Membrane , 2006, Science.

[3]  P. Camilli,et al.  Accessory factors in clathrin-dependent synaptic vesicle endocytosis , 2000, Nature Reviews Neuroscience.

[4]  A. Wandinger-Ness,et al.  Rab 7: an important regulator of late endocytic membrane traffic , 1995, The Journal of cell biology.

[5]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[6]  M. Ohh,et al.  Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau , 2008, Current opinion in oncology.

[7]  W. Kaelin,et al.  Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 , 1998, Molecular and Cellular Biology.

[8]  T. Shuin,et al.  Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters , 2002, Genes, chromosomes & cancer.

[9]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[10]  P. Woodman.  Biogenesis of the Sorting Endosome: The Role of Rab5 , 2000, Traffic.

[11]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[12]  P. Sluijs,et al.  The small GTP-binding protein rab4 controls an early sorting event on the endocytic pathway , 1992, Cell.

[13]  M. Zerial,et al.  Rabaptin-5 is a direct effector of the small GTPase Rab5 in endocytic membrane fusion , 1995, Cell.

[14]  L. Huang,et al.  Hypoxia-inducible Factor and Its Biomedical Relevance* , 2003, Journal of Biological Chemistry.

[15]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[16]  B. Deurs,et al.  Rab7: a key to lysosome biogenesis. , 2000, Molecular biology of the cell.

[17]  Nurgun Kose,et al.  Endocytic Function of von Hippel-Lindau Tumor Suppressor Protein Regulates Surface Localization of Fibroblast Growth Factor Receptor 1 and Cell Motility* , 2006, Journal of Biological Chemistry.

[18]  B. Ebert,et al.  Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo , 2006 .

[19]  S. Schmid,et al.  Regulation of signal transduction by endocytosis. , 2000, Current opinion in cell biology.

[20]  Marino Zerial,et al.  A Novel Rab5 GDP/GTP Exchange Factor Complexed to Rabaptin-5 Links Nucleotide Exchange to Effector Recruitment and Function , 1997, Cell.

[21]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[22]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[23]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[24]  C. Arighi,et al.  Divalent interaction of the GGAs with the Rabaptin‐5–Rabex‐5 complex , 2003, The EMBO journal.

[25]  B. Ebert,et al.  Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. , 2006, The EMBO journal.

[26]  R. Klausner,et al.  The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells , 1999, Molecular and Cellular Biology.

[27]  M. Zerial,et al.  Inhibition of rab5 GTPase activity stimulates membrane fusion in endocytosis. , 1994, The EMBO journal.

[28]  Karl J. Dykema,et al.  Somatic Pairing of Chromosome 19 in Renal Oncocytoma Is Associated with Deregulated ELGN2-Mediated Oxygen-Sensing Response , 2008, PLoS genetics.

[29]  Isabelle Robert,et al.  Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer , 2007, Proceedings of the National Academy of Sciences.

[30]  W. Kaelin,et al.  Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.

[31]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[32]  M. Ivan,et al.  von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. , 2001, Human molecular genetics.

[33]  M. Clatworthy,et al.  Neutrophils from patients with heterozygous germline mutations in the von Hippel Lindau protein (pVHL) display delayed apoptosis and enhanced bacterial phagocytosis. , 2006, Blood.

[34]  M. Zerial,et al.  Expression, purification, and characterization of Rab5 effector complex, rabaptin-5/rabex-5. , 2001, Methods in enzymology.

[35]  W. Kaelin,et al.  Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.

[36]  S. Kiselev,et al.  Apoptotic Cleavage of Rabaptin-5-like Proteins and a Model for Rabaptin-5 Inactivation in Apoptosis , 2006, Cell cycle.

[37]  S. Pfeffer.  Motivating endosome motility , 1999, Nature Cell Biology.